• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Sutro Biopharma Inc.

    5/30/25 4:30:56 PM ET
    $STRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $STRO alert in real time by email
    S-8 1 stro-20250530.htm S-8 S-8

     

    As filed with the Securities and Exchange Commission on May 30, 2025

    Registration No. 333-

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM S-8
    REGISTRATION STATEMENT

    UNDER THE SECURITIES ACT OF 1933

    SUTRO BIOPHARMA, INC.
    (Exact Name of Registrant as Specified in Its Charter)
    ________________________

    Delaware

    47-0926186

    (State or Other Jurisdiction of

    (I.R.S. Employer

    Incorporation or Organization)

    Identification No.)

    111 Oyster Point Blvd.
    South San Francisco, California, 94080
    (650) 881-6500
    (Address of Principal Executive Offices) (Zip Code)

    Amended and Restated

    2021 Equity Inducement Plan

    (Full Title of the Plans)

    Jane Chung, R.Ph.
    Chief Executive Officer
    Sutro Biopharma, Inc.
    111 Oyster Point Blvd.
    South San Francisco, CA 94080
    (Name and Address of Agent for Service)

    (650) 881-6500
    (Telephone Number, including area code, of agent for service)
    ________________________

    Please send copies of all communications to:


    Amanda L. Rose, Esq.
    Ryan Mitteness, Esq.
    Fenwick & West LLP
    555 California Street, 12
    th Floor
    San Francisco, California 94104
    (415) 875-2300
    ________________________

    Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    Large accelerated filer

    ☐

    Accelerated filer

    ☒

    Non-accelerated filer

    ☐

    Smaller reporting company

    ☒

    Emerging growth company

    ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     


     

     

    REGISTRATION OF ADDITIONAL SHARES
    PURSUANT TO GENERAL INSTRUCTION E

    Sutro Biopharma, Inc. (the “Registrant”) is filing this Registration Statement with the Securities and Exchange Commission (the “Commission”) to register 2,250,000 additional shares of common stock available for issuance under the Registrant’s 2021 Equity Inducement Plan (the “2021 Inducement Plan”).

    In accordance with General Instruction E of Form S-8, and only with respect to the common stock issuable under the 2021 Inducement Plan, this Registration Statement hereby incorporates by reference the contents of the Registrant’s Registration Statements on Form S-8 filed with the Commission on August 9, 2021 (Registration No. 333-258603), August 31, 2022 (Registration No. 333-267194), and February 27, 2023 (Registration No. 333-270055) to the extent not superseded hereby.

     


     

     

     

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3. Incorporation of Documents by Reference.

    The following documents filed by the Registrant with the Commission pursuant to the Securities Act and the Securities Exchange Act of 1934, as amended (the “Exchange Act”) are incorporated herein by reference:

    (a) the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Commission on March 13, 2025 pursuant to Section 13 of the Exchange Act;

    (b) all other reports filed pursuant to Section 13(a) or 15(d) of the Exchange Act since the end of the fiscal year covered by the Registrant’s Annual Report on Form 10-K referred to in (a) above; and

    (c) the description of the Registrant’s common stock contained in the Registrant’s registration statement on Form 8-A (File No. 001-38662) filed on September 18, 2018 under Section 12(b) of the Exchange Act, including any amendment or report filed for the purpose of updating such description.

    All documents and definitive proxy or information statements filed by the Registrant pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the filing of this Registration Statement and prior to the filing of a post-effective amendment, which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing such documents, except as to documents or information deemed to have been furnished and not filed in accordance with the rules of the Commission. Unless expressly incorporated into this Registration Statement, a report deemed to be furnished but not filed on Form 8-K prior or subsequent to the date hereof shall not be incorporated by reference into this Registration Statement. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement.

    Item 8. Exhibits.

    Exhibit

    Incorporated by Reference

    Filed

    Number

    Exhibit Description

    Form

    File No.

    Exhibit

    Filing Date

    Herewith

    4.1

    Amended and Restated Certificate of Incorporation of the Registrant.

    10-Q

    001-38662

    3.1

    11/13/2023

    4.2

    Amended and Restated Bylaws of the Registrant.

    8-K

    001-38662

    3.1

    02/24/2023

    4.3

    Form of Registrant’s Common Stock Certificate.

    S-1/A

    333-227103

    4.1

    09/17/2018

    5.1

    Opinion and Consent of Fenwick & West LLP.

    X

    23.1

    Consent of independent registered public accounting firm.

    X

    23.2

    Consent of Fenwick & West LLP (contained in Exhibit 5.1).

    X

    24.1

    Power of Attorney (included on signature page of this Registration Statement).

    X

    99.1

    Amended and Restated 2021 Equity Inducement Plan.

     

     

     

     

    X

    99.2

    Amended Form of Restricted Stock Unit Award Agreement under the Amended and Restated 2021 Equity Inducement Plan.

     

     

     

     

    X

    99.3

    Amended Form of Stock Option Award Agreement under the Amended and Restated 2021 Equity Inducement Plan.

     

     

     

     

    X

    107.1

    Calculation of Registration Fees.

    X

     

     


     

     

    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in South San Francisco, California, on this 30th day of May, 2025.

    SUTRO BIOPHARMA, INC.

    By: /s/ Jane Chung

    Jane Chung

    Chief Executive Officer and Director

     

     


     

     

     

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Jane Chung and David Pauling, and each of them, as his or her true and lawful attorney-in-fact and agent with full power of substitution, for him or her in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his or her substitute, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.

    Signature

    Title

    Date

    /s/ Jane Chung

    Chief Executive Officer and Director

    May 30, 2025

    Jane Chung

    (Principal Executive Officer and
    Principal Financial Officer)

     

    /s/ Connie Matsui

    Director, Chair

    May 30, 2025

    Connie Matsui

    /s/ Michael Dybbs, Ph.D.

    Director

    May 30, 2025

    Michael Dybbs, Ph.D.

    /s/ John G. Freund, M.D.

    Director

    May 30, 2025

    John G. Freund, M.D.

    /s/ Heidi Hunter

    Director

    May 30, 2025

    Heidi Hunter

    /s/ Sukhi Jagpal

    Director

    May 30, 2025

    Sukhi Jagpal

    /s/ Joseph M. Lobacki

    Director

    May 30, 2025

    Joseph M. Lobacki

    /s/ James Panek

    Director

    May 30, 2025

    James Panek

    /s/ Daniel H. Petree

    Director

    May 30, 2025

    Daniel H. Petree

    /s/ Jon Wigginton, M.D.

    Director

    May 30, 2025

    Jon Wigginton, M.D.

     

     

     


    Get the next $STRO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $STRO

    DatePrice TargetRatingAnalyst
    3/17/2025Buy → Neutral
    H.C. Wainwright
    3/14/2025Mkt Outperform → Mkt Perform
    Citizens JMP
    3/14/2025$8.00 → $2.00Outperform → Neutral
    Wedbush
    3/14/2025$11.00 → $1.00Buy → Underperform
    BofA Securities
    5/8/2024$12.00Buy
    BofA Securities
    11/9/2023$12.00Buy
    Deutsche Bank
    10/6/2023$10.00Outperform
    Oppenheimer
    3/21/2023$15.00 → $8.00Overweight → Equal Weight
    Wells Fargo
    More analyst ratings

    $STRO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Sutro Biopharma Appoints Greg Chow as Chief Financial Officer

      SOUTH SAN FRANCISCO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the appointment of Greg Chow as Chief Financial Officer (CFO), effective June 2, 2025. Mr. Chow brings over 25 years of executive leadership experience across corporate finance, capital markets, investment banking, financial accounting, and drug development operations. "We are delighted to welcome Greg to Sutro's executive leadership team," said Jane Chung, Chief Executive Officer of Sutro. "Greg brings a strong track record of driving financial discipline, o

      6/2/25 8:00:00 AM ET
      $STRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights

      - Sharpened product candidate focus on its next-generation ADC portfolio, following strategic review and pipeline reprioritization - - Promising preclinical results with STRO-004 and dual-payload ADC, as well as STRO-006 programs presented at AACR 2025 and PEGS, respectively - - Three INDs for wholly-owned programs anticipated in next 3 years, beginning with potential best-in-class Tissue Factor ADC, STRO-004, planned for 2H 2025 - - IND-enabling toxicology study ongoing for one program within Astellas iADC collaboration, triggering $7.5 million milestone payment to Sutro - - Cash, cash equivalents and marketable securities as of March 31, 2025 of $249.0 million, with cas

      5/8/25 4:31:42 PM ET
      $STRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sutro Biopharma to Participate in Upcoming Investor Conferences

      SOUTH SAN FRANCISCO, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that management will participate in two upcoming investor conferences. Conference Details: The Citizens Life Sciences ConferenceDate: May 7-8, 2025Location: New York, NY BofA Securities 2025 Health Care ConferenceDate: May 13-15, 2025Location: Las Vegas, NV Webcasts of the presentations will be accessible through the News & Events page of the Investor Relations section of the Company's website at www.sutrobio.com. Archived replays will be available

      5/1/25 4:05:00 PM ET
      $STRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $STRO
    SEC Filings

    See more
    • SEC Form 8-K filed by Sutro Biopharma Inc.

      8-K - SUTRO BIOPHARMA, INC. (0001382101) (Filer)

      6/10/25 4:30:18 PM ET
      $STRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sutro Biopharma Inc. filed SEC Form 8-K: Leadership Update

      8-K - SUTRO BIOPHARMA, INC. (0001382101) (Filer)

      6/2/25 4:01:20 PM ET
      $STRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 filed by Sutro Biopharma Inc.

      S-8 - SUTRO BIOPHARMA, INC. (0001382101) (Filer)

      5/30/25 4:30:56 PM ET
      $STRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $STRO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Sutro Biopharma Inc.

      SC 13G/A - SUTRO BIOPHARMA, INC. (0001382101) (Subject)

      11/14/24 7:54:45 PM ET
      $STRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Sutro Biopharma Inc.

      SC 13G/A - SUTRO BIOPHARMA, INC. (0001382101) (Subject)

      11/14/24 4:30:53 PM ET
      $STRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Sutro Biopharma Inc.

      SC 13G/A - SUTRO BIOPHARMA, INC. (0001382101) (Subject)

      11/13/24 4:30:25 PM ET
      $STRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $STRO
    Financials

    Live finance-specific insights

    See more
    • Sutro Biopharma Reports Full Year 2024 Financial Results and Business Highlights

      – Sutro announced a strategic portfolio review resulting in prioritization of wholly-owned next-generation ADC programs; Key management changes announced as part of transition – – Cash, cash equivalents and marketable securities as of December 31, 2024 of $316.9 million, with cash runway expected into at least Q4 2026, excluding anticipated milestones from existing collaborations – – Conference call today at 2:00 p.m. PT / 5:00 p.m. ET – SOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today reported its financial resu

      3/13/25 4:07:00 PM ET
      $STRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sutro Biopharma Announces Strategic Portfolio Review Resulting in the Prioritization of its Next-Generation ADC Pipeline

      – Sutro will rapidly advance next-generation exatecan and dual-payload ADC programs; luveltamab tazevibulin development to be deprioritized as Sutro continues to seek a partner – – Three INDs for wholly-owned programs expected in the next 3 years, beginning with novel Tissue Factor ADC, STRO-004, planned for 2H 2025 – – Jane Chung, President and COO, to succeed Bill Newell as CEO and Board Director – – Cash, cash equivalents and marketable securities as of December 31, 2024 of $316.9 million, with cash runway expected into at least Q4 2026, excluding anticipated milestones from existing collaborations – – Conference call today at 2:00 p.m. PT/ 5:00 p.m. ET – SOUTH SAN FRANCISCO, Calif

      3/13/25 4:05:00 PM ET
      $STRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sutro Biopharma to Provide Data Update on STRO-002 and Plans for Registrational Path Forward in Advanced Ovarian Cancer

      - Conference call and webcast to be held on Monday, January 9, 2023 at 1:30 pm PT, or 4:30 pm ET - SOUTH SAN FRANCISCO, Calif., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced it will host a conference call and webcast to present data from its Phase 1 dose-expansion trial and a registrational path forward for STRO-002, an ADC being developed for the treatment of advanced ovarian cancer. In addition to members of the Sutro management team, the call will feature Dr. R. Wendel Naumann, Investigator in the STRO-002-GM1 stud

      12/21/22 8:00:00 AM ET
      $STRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $STRO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Wigginton Jon Marc

      4 - SUTRO BIOPHARMA, INC. (0001382101) (Issuer)

      6/10/25 4:14:14 PM ET
      $STRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Petree Daniel H

      4 - SUTRO BIOPHARMA, INC. (0001382101) (Issuer)

      6/10/25 4:13:33 PM ET
      $STRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Panek James P

      4 - SUTRO BIOPHARMA, INC. (0001382101) (Issuer)

      6/10/25 4:12:50 PM ET
      $STRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $STRO
    Leadership Updates

    Live Leadership Updates

    See more
    • Sutro Biopharma Appoints Greg Chow as Chief Financial Officer

      SOUTH SAN FRANCISCO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the appointment of Greg Chow as Chief Financial Officer (CFO), effective June 2, 2025. Mr. Chow brings over 25 years of executive leadership experience across corporate finance, capital markets, investment banking, financial accounting, and drug development operations. "We are delighted to welcome Greg to Sutro's executive leadership team," said Jane Chung, Chief Executive Officer of Sutro. "Greg brings a strong track record of driving financial discipline, o

      6/2/25 8:00:00 AM ET
      $STRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sutro Biopharma Reports Second Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones

      - Sutro will present updated data from the ongoing Phase 1b study of luvelta in combination with bevacizumab in a poster presentation at ESMO 2024; expansion study is ongoing with data expected in the first half of 2025 - - REFRαME-O1 Part 2 (randomized portion) of the Phase 3 trial of luvelta for treatment of platinum-resistant ovarian cancer (PROC) is underway - - REFRαME-P1, a registration-enabling trial of luvelta for pediatric patients with CBFA2T3::GLIS2 (CBF/GLIS; RAM phenotype) AML, is expected to be initiated in the second half of 2024 - - A Phase 2 trial of luvelta for the treatment of NSCLC is expected to initiate in the second half of 2024, with initial data expect

      8/13/24 4:30:00 PM ET
      $STRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sutro Biopharma Appoints Dr. Barbara Leyman as Chief Business Development Officer

      SOUTH SAN FRANCISCO, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the appointment of Barbara Leyman, Ph.D., as Chief Business Development Officer, effective July 8, 2024. Dr. Leyman brings 20 years of life science industry business development, investing, and corporate strategy experience to Sutro. "We are thrilled to welcome Dr. Leyman at a pivotal time for Sutro, as we advance luvelta in two registration-directed trials in both ovarian cancer and a rare pediatric cancer and continue to leverage our proprieta

      7/9/24 8:00:00 AM ET
      $STRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $STRO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Sutro Biopharma downgraded by H.C. Wainwright

      H.C. Wainwright downgraded Sutro Biopharma from Buy to Neutral

      3/17/25 8:19:45 AM ET
      $STRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sutro Biopharma downgraded by Citizens JMP

      Citizens JMP downgraded Sutro Biopharma from Mkt Outperform to Mkt Perform

      3/14/25 7:42:27 AM ET
      $STRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sutro Biopharma downgraded by Wedbush with a new price target

      Wedbush downgraded Sutro Biopharma from Outperform to Neutral and set a new price target of $2.00 from $8.00 previously

      3/14/25 7:41:51 AM ET
      $STRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care